Response Rate of Lapatinib Plus Capecitabine After Neratinib Progression
The objective response rate (ORR) of lapatinib plus capecitabine after progression on neratinib is approximately 26.7% based on the NALA trial, where this combination served as the control arm in heavily pretreated HER2-positive metastatic breast cancer patients. 1
Evidence from the NALA Trial
The most relevant data comes from the phase III NALA trial, which directly compared neratinib plus capecitabine versus lapatinib plus capecitabine in patients who had received ≥2 prior lines of HER2-targeted therapy in the metastatic setting 1:
- ORR: 26.7% for lapatinib plus capecitabine 1
- Clinical benefit rate: 35.6% 1
- Median duration of response: 5.6 months 1
- Median PFS: Not explicitly stated for lapatinib arm alone, but neratinib showed HR 0.76 (95% CI, 0.63–0.93) 1
Approximately 30% of NALA patients had received ≥3 prior treatment lines, and about one-third had received prior trastuzumab, pertuzumab, and T-DM1 1. This represents a heavily pretreated population similar to what you would encounter after neratinib progression.
Context from Earlier-Line Studies
For comparison, in less heavily pretreated populations (trastuzumab-refractory but earlier-line therapy), lapatinib plus capecitabine demonstrated higher response rates 1:
- Time to progression: 8.4 months versus 4.4 months for capecitabine alone (HR 0.49; 95% CI, 0.34–0.71; P<.001) 1
- Median OS: 75.0 weeks versus 64.7 weeks for capecitabine alone 1
Important Clinical Considerations
Toxicity Profile
The combination carries significant toxicity that must be managed 2:
- Diarrhea: 65% all grades, 13% grade 3 2
- Palmar-plantar erythrodysesthesia: 53% all grades, 12% grade 3 2
- Nausea: 44% and vomiting: 26% 2
Alternative Considerations
After neratinib progression, current guidelines prioritize other options over lapatinib plus capecitabine 1:
- Trastuzumab deruxtecan is preferred after 2+ prior HER2-targeted regimens, with ORR of 60.9% and median PFS of 16.4 months 1
- Tucatinib plus trastuzumab plus capecitabine is particularly valuable for patients with brain metastases 1
Real-World Data
A real-world study of 92 patients with HER2-positive MBC receiving lapatinib-based regimens showed 3:
- ORR: 21.7% overall
- Median PFS: 5.8 months overall
- Median PFS with lapatinib plus capecitabine specifically: 8.1 months 3
Clinical Bottom Line
While lapatinib plus capecitabine remains an NCCN-endorsed option for HER2-positive metastatic breast cancer after progression on trastuzumab-containing regimens 1, the expected ORR of approximately 27% after neratinib progression is modest 1. This combination would typically be considered only after exhausting preferred options like trastuzumab deruxtecan, particularly given the availability of more effective alternatives in the current treatment landscape 1.